At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 898 enrolled
Drug / intervention
ALD403 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
In Brief
A Phase 3 clinical trial evaluating ALD403 and Placebo for Migraine Disorders. Completed, enrolled 898 participants across 87 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesGeorgia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedSep 2015
Primary CompletionFeb 2017
Study CompletionDec 2017
TodayJul 2026
First PostedSep 25, 2015
Enrollment StartSep 1, 2015
Primary CompletionFeb 1, 2017
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.8 years ago
Interventions
ALD403drug
Placebodrug